Media releases

We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.

Media releases

PolyPeptide publishes invitation to the annual General Meeting 2023

22 Mar 2023 - Baar, 22 March 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients (the “Company”), published today the […]

Read more
Media releases

Monika Casanova joining PolyPeptide as CHRO and member of the PMC

9 May 2022 - With 19 years of HR experience, the native German most recently worked as head of global HR for a building materials company.

Read more
Media releases

PolyPeptide announces results of the annual General Meeting 2022

26 Apr 2022 - PolyPeptide Group AG (PolyPeptide), a global leader in peptide development and manufacturing, today announced that the shareholders approved all proposals put forward by the Board of […]

Read more
Media releases

PolyPeptide publishes invitation to the annual General Meeting 2022

1 Apr 2022 - PolyPeptide Group AG (PolyPeptide), a global leader in peptide custom development and manufacturing, published today the invitation to its first annual General Meeting which will take […]

Read more
Media releases

PolyPeptide customer Cara Therapeutics with FDA approval for novel treatment of moderate-to-severe pruritus in hemodialysis patients

1 Sep 2021 - Long-term collaborative development process for peptide API successfully completed and continued with commercial supply agreement PolyPeptide is pleased to announce that its customer Cara Therapeutics (Nasdaq: […]

Read more
Media releases

PolyPeptide Group appoints Raymond De Vré as new Chief Executive Officer

16 Feb 2021 - PolyPeptide Group, a global leader in peptide manufacturing and development, today announced the appointment of  as its new Chief Executive Officer. He will succeed Jane Salik […]

Read more
Media releases

PolyPeptide Group Selected by Novavax to Manufacture Critical Intermediates of Matrix-M™ Adjuvant for its COVID-19 Vaccine

4 Jun 2020 - The PolyPeptide Group, a global Contract Development and Manufacturing Organization (CDMO) for Peptide, Peptidomimetic and other Drug Substances, has announced that it has partnered with Novavax […]

Read more